Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
Karthik Suresh, Jarushka Naidoo, Qiong Zhong, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 10, pp. 4305-4315
Open Access | Times Cited: 139

Showing 1-25 of 139 citing articles:

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002435-e002435
Open Access | Times Cited: 568
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Weiting Qin, Li-Peng Hu, Xueli Zhang, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 332
Moving towards personalized treatments of immune-related adverse events
Khashayar Esfahani, Arielle Elkrief, Cassandra Calabrese, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 8, pp. 504-515
Closed Access | Times Cited: 255
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Ryan J. Sullivan, Jeffrey S. Weber
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 7, pp. 495-508
Closed Access | Times Cited: 194
Immune-related adverse events in various organs caused by immune checkpoint inhibitors
Naoko Okiyama, Ryota Tanaka
Allergology International (2022) Vol. 71, Iss. 2, pp. 169-178
Open Access | Times Cited: 86
Clinical and translational attributes of immune-related adverse events
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 40
Pulmonary toxicity of immune checkpoint immunotherapy
Mohammad I. Ghanbar, Karthik Suresh
Journal of Clinical Investigation (2024) Vol. 134, Iss. 2
Open Access | Times Cited: 23
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
John B.A.G. Haanen, Marc S. Ernstoff, Yinghong Wang, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000604-e000604
Open Access | Times Cited: 135
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research
Douglas B. Johnson, Kerry L. Reynolds, Ryan J. Sullivan, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 8, pp. e398-e404
Closed Access | Times Cited: 98
Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
Xiangling Chu, Jing Zhao, Juan Zhou, et al.
Lung Cancer (2020) Vol. 150, pp. 76-82
Closed Access | Times Cited: 94
Antigen presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier immunity
Anukul T. Shenoy, C. Lyon De Ana, E.I. Arafa, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 87
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
Qin Zhang, Liansha Tang, Yuwen Zhou, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 80
Chronic immune checkpoint inhibitor pneumonitis
Jarushka Naidoo, Tricia R. Cottrell, Evan J. Lipson, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000840-e000840
Open Access | Times Cited: 79
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance
Arthur Géraud, Paul Gougis, Aurore Vozy, et al.
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 85-112
Open Access | Times Cited: 75
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
Francesco Cortiula, Bart Reymen, Solange Peters, et al.
Annals of Oncology (2022) Vol. 33, Iss. 9, pp. 893-908
Open Access | Times Cited: 65
Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury
Zengfu Zhang, Jialin Zhou, Vivek Verma, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 61
Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
David Jungpa Lee, Howard J. Lee, Jocelyn R. Farmer, et al.
Current Cardiology Reports (2021) Vol. 23, Iss. 8
Closed Access | Times Cited: 60
Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
Jianqiong Yin, Yuanjun Wu, Xue Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 56
Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
Amelie Franken, Pierre Van Mol, Sam Vanmassenhove, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 9, pp. e005323-e005323
Open Access | Times Cited: 44
Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
Betul Ibis, Konstantinos Aliazis, Carol Cao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 41
Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management
Meixi Lin, Dan Zang, Chenguang Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 16
Toxicity in the era of immune checkpoint inhibitor therapy
Synat Keam, Naimah Turner, Fernanda G. Kugeratski, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 14
Corticosteroid-resistant immune-related adverse events: a systematic review
Eveline Daetwyler, Till Wallrabenstein, David König, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e007409-e007409
Open Access | Times Cited: 13
Radiation-induced lung injury: from mechanism to prognosis and drug therapy
Sheng Wang, Duo Xu, Lingyan Xiao, et al.
Radiation Oncology (2025) Vol. 20, Iss. 1
Open Access | Times Cited: 1
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
Xiaoyang Zhai, Jian Zhang, Yaru Tian, et al.
Cancer Biology and Medicine (2020) Vol. 17, Iss. 3, pp. 599-611
Open Access | Times Cited: 70
Page 1 - Next Page

Scroll to top